Sanofi-Aventis by its own admission has “a big patent-expiration problem,” Cramer said during Friday’s Mad Money. “And when drugs go off patent, pharmaceutical companies’ profits get obliterated.”
Drugs that accounted for about 41% of Sanofi-Aventis’ 2009 sales could lose patent protection in the coming years, including its top two: the blood thinners, Plavix, which it shares with Bristol-Myers Squibb , and Lovenox. These drugs combined represent up to 9.7 billion euros in worldwide revenues.
Still, SNY claims that it has other treatments to carry the company in the meantime, namely the diabetes drug Lantus. And there’s Multaq for irregular heart rhythms, though it’s still too early to tell how big it will be. Sanofi also runs a strong vaccine division, which is number one in the word. Plus, Cramer said there’s a lot of promise in the company’s oncology pipeline, as much as any of the names he recommended during Mad Money’s cancer-research week. 
So is Sanofi-Aventis staring into a troubled future, or is Wall Street missing the company’s potential? Cramer went to CEO Chris Viehbacher to find out. Watch the video for the full interview.
Cramer’s charitable trust owns Bristol-Myers Squibb.
Call Cramer: 1-800-743-CNBC
Questions for Cramer?
Questions, comments, suggestions for the Mad Money website? email@example.com